Business

The Oxford COVID-19 vaccine triggers an immune response in tests

As reported by The Lancet, the vaccine developed in conjunction with AstraZeneca is one of the options that is showing the most encouraging results

Read for 3 min


The Oxford COVID-19 vaccine triggers an immune response in tests
The Oxford COVID-19 vaccine triggers an immune response in tests

The new Covid-19 vaccination developed in the Oxford University next to the pharmacist Astra Zeneca Great expectations were raised on Monday as the results after the test phase were encouraging.

According to the magazine The lancetis one of the options that shows the most possibilities that it can be distributed to the entire population in the future. It was found to be safe and triggered an immune response in its test phase.

The study included 1,077 people aged 18 to 55 with no history of coronavirus and was conducted in five British hospitals from late April to late May.

The vaccine, Call ChAdOx1 nCoV-19is made from a genetically modified virus that, according to chimpanzees, causes a cold BBC World. It has undergone major changes so that it cannot cause infections in humans and it “looks” like COVID-19.

The performance of this vaccine is believed to be due to the fact that it provides double protection against the virus. First, it would develop the production of antibodies and T cells, a type of white blood cell that coordinate the immune system. On the other hand, the organism could recognize infected cells in the long term.

The performance of this vaccine is attributed to the fact that it includes double protection against the virus / Image: Depositphotos.com

“There is still a long way to go before we can confirm that our vaccine will help fight the COVID-19 pandemic, but our initial results are certainly encouraging,” said Sarah Gilbert, a researcher at Oxford University’s media portal Halftime.

The study is still too new to determine exactly how long protection will take The lancet.

90% of people showed neutralizing antibody development after one dose. Only ten people received an additional dose and all neutralizing antibodies developed.

“We don’t know how high the protection needs to be, but we can maximize the response with a second dose,” he said BBC Andrew Pollard, head of the Oxford research group.

There were no dangerous reactions to the vaccine, but 70% of the subjects developed fever and headache, symptoms that the researchers thought could be treated with acetaminophen.

Similar Posts